Pregnant WomenERASNCT06753058
ERAS Protocol on Maternal and Fetal Outcomes Following Elective Cesarean Section
A study testing 25 gram of maltodextrin in 330 mL , Nutricia Fantomalt 4 Gram, Nutri Gıda Ürünleri San. ve Tic. A.Ş., Istanbul, Türkiye, 2 h prior to surgery. and Mother baby bonding in people with Pregnant Women and Enhanced Recovery After Surgery (ERAS) Protocol, run by Gazi University at 1 site in Turkey (Türkiye).
Trial summary
The goal of this observational study is to investigate the maternal, fetal, and neonatal outcomes in parturients scheduled to undergo elective cesarean section (CS) receiving either standard care or enhanced recovery after surgery (ERAS) protocol. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Pregnant Women, Enhanced Recovery After Surgery (ERAS) Protocol
- What is being tested?
- 25 gram of maltodextrin in 330 mL , Nutricia Fantomalt 4 Gram, Nutri Gıda Ürünleri San. ve Tic. A.Ş., Istanbul, Türkiye, 2 h prior to surgery. and Mother baby bonding
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 450 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jun 2021to 1 Jun 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- American Society of Anesthesiologists (ASA) II or III term pregnant women aged ≥18 years scheduled to undergo elective CS under spinal anesthesia between June 2021 and June 2023 in Gazi University
Who cannot join
- Parturients younger than <18 years old with fetal compromise, ASA IV or V physical status and emergency cases, medical contraindication to regional anesthesia particularly spinal block
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Gazi University School of Medicine Department of Anesthesiology and Reanimation
Ankara, 06500
About this study
Official title: ERAS Protocol on Maternal and Fetal Outcomes Following Elective Cesarean Section: a Controlled Trial
The goal of this observational study is to investigate the maternal, fetal, and neonatal outcomes in parturients scheduled to undergo elective cesarean section (CS) receiving either standard care or enhanced recovery after surgery (ERAS) protocol.
Primary purpose is to learn if implementing ERAS protocol can improve maternal outcomes in pregnant women aged greater than 18 years scheduled to undergo elective CS under spinal anesthesia using patient reported outcome mesaure (PROM).
Read more
Secondary purpose is to learn if implementation of maternal ERAS protocol can improve neonatal outcome in terms of nutrition and breastfeeding.
The main questions that aims to answer are maternal recovery outcome measure determined by obstetric quality recovery score (ObsQoR) which has been known as a patient reported outcome mesaure (PROM) and neonatal outcome assessed by pediatricians.
Primary outcome measure is improved maternal recovery in term of ObsQoR in the ERAS pathway.
Secondary outcome measure is improved neonatal outcome in terms of nutrition and breastfeeding in the ERAS pathway.
Read the detailed description
Methods After obtaining approval of the institutional ethics committee (Decision number: 502/Date: 31.05.2021) and written informed consent from the parturients, data were collected prospectively in 450 ASA II or III term pregnant women aged ≥18 years scheduled to undergo elective CS under spinal anesthesia between June 2021 and June 2023. Gazi University Hospital, which is a re-accredited tertiary care referral center by ESAIC (European Society of Anaesthesiology and Intensive Care), has an annual rate of approximately 1400 deliveries. Parturients younger than <18 years old with fetal compromise, ASA IV or V physical status and emergency cases were not included in this study. The ERAS protocol introduced for our unit was adapted from the SOAP. Following approval of the ERAS protocol by the obstetric team and the participants, two groups were assigned as; ERAS group (n=150) and control group (n=300) who would receive standard care of the unit. The data of the parturients having standard care were compared with those who were enrolled in the ERAS pathway.
Features of ERAS implementation and standard care in the study Step 1. Preoperative (Antepartum) Components
- Enrolled patients were seen in the antenatal clinic to give face to face education including information about fasting, CS and/or anesthesia, antimicrobial prophylaxis, skin washing, breastfeeding preparation and support by the principal researcher anesthesiologist for ERAS pathway to improve patient understanding and engagement in their own care.
- Principally fasting 6 hours (h) for solids and 2 h for clear fluids was provided. To standardize fasting duration according to the scheduled time of surgery in the ERAS group, parturients who were scheduled for CS before 12:00 PM were allowed to have breakfast at 2:00 AM, while the rest scheduled for CS after 12:00 PM were allowed to have breakfast at 6:00 AM. On the morning of surgery, parturients either diabetic or non-diabetic in the ERAS implemented group were given a carbohydrate solution prepared by the principal researcher anesthesiologist containing 25 g of maltodextrin in 330 mL approximately 2 h prior to surgery. The control group fasted after 12:00 AM regardless of the scheduled CS time and no carbohydrate solution was administered prior to surgery.
- Anemia screening and treatment for hemoglobin optimization was done in both groups.
Step 2. Perioperative (Intrapartum) Components
- Standard intravenous (IV) antibiotic prophylaxis as per hospital guidelines was done in both groups (IV Cefazolin 2 gram in case of no known allergy history).
- Management of anesthesia/analgesia (neuraxial 100 microgram of morphine and 10 microgram of fentanyl), maintenance of fluid and surgical techniques were similar in both groups. As per our obstetric anesthesia division practice [16], weight-height adjusted dose of hyperbaric bupivacaine 0.5% with morphine plus fentanyl was used during co-loading of 500 mL of colloid (VOLUHES, HES 130/0.4, 6% I.V., Polifarma, Türkiye) for spinal anesthesia and spinal anesthesia induced hypotension was treated with 10 mg of ephedrine (only available vasopressor drug in the country) in IV bolus doses in both groups.
- Despite all parturients in both groups received 10 mg of IV metoclopramide prophylactically, parturients in the ERAS implemented group received IV 1.5 mg of the 5-HT3 antagonist granisetron additionally. In both groups, in case of risk factors for intraoperative and postoperative nausea and vomiting (PONV), IV 4 mg of dexamethasone was added.
- To maintain normothermia body temperature loss was prevented using under-patient-mattress-blankets and warmers along with the control of the operating theatre temperature.
- After the delivery of the baby, uterotonics were administered as per hospital guidelines (50 microgram of carbetocin IV bolus was given and followed by 20 IU of oxytocin in 1000 ml of normal saline infusion was started at a rate of 2.5-7.5 IU/ hour) in both groups.
Delayed cord clamping was not performed in any of the groups by the obstetricians.
Step 3. Postoperative Components
- In both groups who are at risk for deep vein thrombosis, prophylaxis was provided using pneumatic compression stockings.
- Blood glucose monitoring was conducted only in diabetic patients and those with symptoms of hypoglycemia during follow-up.
- In the ERAS implemented group, the diet management plan was as follows:
- drinking clear water was started at 2 h postoperatively
- eating liquid diet (regime I or II) was started at 4 h
- Regime I (R-I) is a clear liquid diet that contains pulp-free, grain-free liquid drinks such as sweetened tea, fruit juice, compote water, lemonade, meat and chicken broth.
- Regime II (R-II) is a soft diet that consists of soft, easily chewable and digestible foods such as; light soups, mashed and boiled potatoes, puddings and liquid drinks, etc.
- eating normal diet (regime III-IV) was started at 6 h In the control group, the oral intake -diet management plan was as follows:
- drinking water at 6 h postoperatively
- eating diet R I-II a few h later
- eating diet R III-IV after 1st flatus
- Parturients in the ERAS implemented group were encouraged to chew gum with early feeding, while patients in the control group were not.
- The urinary catheter was removed just before mobilization in the ERAS implemented group, whereas it was removed when urine output reached to 1000 mL as per clinical conventional procedure in the control group.
- In the ERAS implemented group, mother-baby contact to promote early bonding was established, and both mother and baby were encouraged for breastfeeding. In the control group, only mother-baby contact was facilitated without proactive breastfeeding encouragement.
- Prior to discharge, both groups were asked to fill out the validated Turkish version of the ObsQoR-11 with 11-point Likert scale. These forms were collected.
Recorded parameters;
- maternal demographics, comorbidities with medications and history (drug allergy, surgical and obstetric)
- preoperative duration of fasting for fluid and solid food, time to intake of 1st postoperative water, regimen I-II and regimen III-IV
- time to mobilization, urinary catheter removal and flatus and LOS for mother (in hours)
- postoperative pain within 24 h of the surgery was assessed for all patients using VAS scores at postoperative 24 h in rest and extra analgesic requirement
- validated Turkish version of 11-item ObsQoR score with an 11-point numerical Likert scale (0 being strongly negative, 10 being strongly positive) resulting maximum score of 110.
- postoperative complications (hypoglycemia, hypotension, PONV)
- newborn demographics and Apgar scores, umbilical cord gas analysis, newborn LOS in days
- need for follow-up in the ward or newborn intensive care unit (NICU) for transient tachypnea of the newborn (TTN) or phototherapy
- status of mother-baby bonding and breastfeeding
- Being tested
- 25 gram of maltodextrin in 330 mL , Nutricia Fantomalt 4 Gram, Nutri Gıda Ürünleri San. ve Tic. A.Ş., Istanbul, Türkiye, 2 h prior to surgery., Mother baby bonding
- Keywords
- enhanced reocery after surgery, obstetric quality -of-recovery score, cesarean section, spinal anesthesia, newborn well being
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
25 gram of maltodextrin in 330 mL , Nutricia Fantomalt 4 Gram, Nutri Gıda Ürünleri San. ve Tic. A.Ş., Istanbul, Türkiye, 2 h prior to surgery.Dietary supplement
Although 45 g of different carbohydrate solutions either Gatorade 54 g carbohydrate or clear apple juice 56 g carbohydrate in non-diabetic women have been recommended by SOAP, we preferred 25 g of carbohydrate, fantomalt, nutricia, diluted in the 330 mL in both diabetic and non-diabetic pregnant women.
Mother baby bondingBehavioural
In the ERAS implemented group, mother-baby contact to promote early bonding was established, and both mother and baby were encouraged for breastfeeding. In the control group, only mother-baby contact was facilitated without proactive breastfeeding encouragement.
| Study group | Role | What they receive |
|---|---|---|
| STANDARD CARE (CONTROL) | No intervention | Standard care as control includes ROUTINE preoperative, peroperative and postoperative approach of the institution for the management of cesraean delivery under spinal anesthesia. |
| ERAS PATHWAY | Experimental | ERAS INTERVENTION includes 3 steps:
1. preoperative components (face to face education/information about fasting, Cesarean Section and/or anesthesia, antimicrobial prophylaxis, breastfeeding preparation and support, fasting schedule, anemia screening-hemoglobin optimization if needed),
2. peroperative components (antibiotic and antiemetic prophylaxis, management of neuraxial anesthesia, maintenance of normothermia, uterotonic use), 3. postoperative components (early oral intake/urinary catheter removal/mobilization, early mother-newborn bonding and encouraged breastfeeding). Receives: Dietary Supplement: 25 gram of maltodextrin in 330 mL , Nutricia Fantomalt 4 Gram, Nutri Gıda Ürünleri San. ve Tic. A.Ş., Istanbul, Türkiye, 2 h prior to surgery.; Behavioral: Mother baby bonding |
What is being measured
The primary outcome is the main question the study is designed to answer.
improved maternal recovery in term of ObsQoR in the ERAS pathway
Primary outcome measure is described as maternal recovery outcome measure determined by obstetric quality recovery score (ObsQoR) which has been known as a patient reported outcome mesaure (PROM) and neonatal outcome assessed by pediatricians.
ObsQoR-11 scores with Likert scale corresponds to; zero being very poor and 110 being excellent
Measured: From enrollment to the end of ERAS or control postpartum 24 hours
Secondary outcomes (1)
implementation of maternal ERAS protocol improves newborn nutrition and breastfeeding
improved neonatal outcome in the ERAS pathway; nutrition-breastfeeding, higher number of newborns having full breast feeding than formula feeding
Measured: From enrollment to the end of ERAS or control postpartum 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Dec 2024
- Study start1 Jun 2021
- Primary completion1 Jun 2023
- Study completion1 Jun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Pregnant WomenStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- In this interventional study, Enhanced Recovery After Surgery (ERAS) protocol for cesarean has been planned to apply to the parturients who accepted to participate to the study. Unfortunately randomization cannot be done since the strategy for assigning participants to apply ERAS intervention was based on the obstetric team's preference first. The rest of the parturients were regarded as the control group (standard care) who did not receive ERAS intervention.
- Masking
- None (open label)
- Enrolment
- 450 participants (actual)
Sponsor and investigators
- Lead sponsor
- Gazi University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Berrin Gunaydin, Gazi University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06753058
- Sponsor's protocol ID
- Decision no: 502/31.05.2021
- Acronym
- ERAS
- Status last verified
- Dec 2024
- First submitted
- 5 Dec 2024
- Last updated
- 31 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: only IPD used in the results publication
Publications
Ozdemir MG, Gunaydin B, Bayram M, Hirfanoglu IM. Effect of enhanced recovery after surgery (ERAS) protocol on maternal and fetal outcomes following elective cesarean section: an observational trial. BMC Pregnancy Childbirth. 2025 Apr 29;25(1):517. doi: 10.1186/s12884-025-07583-3.
PubMed 40301800
Study at a glance
From the registry record, last updated by the sponsor on 31 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ERAS Protocol on Maternal and Fetal Outcomes Following Elective Cesarean Section: a Controlled Trial
- ClinicalTrials.gov ID
- NCT06753058
- Acronym / sponsor ID
- ERAS / Decision no: 502/31.05.2021
- Keywords
- enhanced reocery after surgery, obstetric quality -of-recovery score, cesarean section, spinal anesthesia, newborn well being
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 450 participants (actual)
- Lead sponsor
- Gazi UniversityUniversity, hospital or other
- Study start
- 1 Jun 2021 (actual)
- Primary completion
- 1 Jun 2023 (actual)
- Study completion
- 1 Jun 2023 (actual)
- First posted
- 31 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to investigate the maternal, fetal, and neonatal outcomes in parturients scheduled to undergo elective cesarean section (CS) receiving either standard care or enhanced recovery after surgery (ERAS) protocol.
Primary purpose is to learn if implementing ERAS protocol can improve maternal outcomes in pregnant women aged greater than 18 years scheduled to undergo elective CS under spinal anesthesia using patient reported outcome mesaure (PROM).
Secondary purpose is to learn if implementation of maternal ERAS protocol can improve neonatal outcome in terms of nutrition and breastfeeding.
The main questions that aims to answer are maternal recovery outcome measure determined by obstetric quality recovery score (ObsQoR) which has been known as a patient reported outcome mesaure (PROM) and neonatal outcome assessed by pediatricians.
Primary outcome measure is improved maternal recovery in term of ObsQoR in the ERAS pathway.
Secondary outcome measure is improved neonatal outcome in terms of nutrition and breastfeeding in the ERAS pathway.
Detailed description
Methods After obtaining approval of the institutional ethics committee (Decision number: 502/Date: 31.05.2021) and written informed consent from the parturients, data were collected prospectively in 450 ASA II or III term pregnant women aged ≥18 years scheduled to undergo elective CS under spinal anesthesia between June 2021 and June 2023. Gazi University Hospital, which is a re-accredited tertiary care referral center by ESAIC (European Society of Anaesthesiology and Intensive Care), has an annual rate of approximately 1400 deliveries. Parturients younger than <18 years old with fetal compromise, ASA IV or V physical status and emergency cases were not included in this study. The ERAS protocol introduced for our unit was adapted from the SOAP. Following approval of the ERAS protocol by the obstetric team and the participants, two groups were assigned as; ERAS group (n=150) and control group (n=300) who would receive standard care of the unit. The data of the parturients having standard care were compared with those who were enrolled in the ERAS pathway.
Features of ERAS implementation and standard care in the study Step 1. Preoperative (Antepartum) Components
- Enrolled patients were seen in the antenatal clinic to give face to face education including information about fasting, CS and/or anesthesia, antimicrobial prophylaxis, skin washing, breastfeeding preparation and support by the principal researcher anesthesiologist for ERAS pathway to improve patient understanding and engagement in their own care.
- Principally fasting 6 hours (h) for solids and 2 h for clear fluids was provided. To standardize fasting duration according to the scheduled time of surgery in the ERAS group, parturients who were scheduled for CS before 12:00 PM were allowed to have breakfast at 2:00 AM, while the rest scheduled for CS after 12:00 PM were allowed to have breakfast at 6:00 AM. On the morning of surgery, parturients either diabetic or non-diabetic in the ERAS implemented group were given a carbohydrate solution prepared by the principal researcher anesthesiologist containing 25 g of maltodextrin in 330 mL approximately 2 h prior to surgery. The control group fasted after 12:00 AM regardless of the scheduled CS time and no carbohydrate solution was administered prior to surgery.
- Anemia screening and treatment for hemoglobin optimization was done in both groups.
Step 2. Perioperative (Intrapartum) Components
- Standard intravenous (IV) antibiotic prophylaxis as per hospital guidelines was done in both groups (IV Cefazolin 2 gram in case of no known allergy history).
- Management of anesthesia/analgesia (neuraxial 100 microgram of morphine and 10 microgram of fentanyl), maintenance of fluid and surgical techniques were similar in both groups. As per our obstetric anesthesia division practice [16], weight-height adjusted dose of hyperbaric bupivacaine 0.5% with morphine plus fentanyl was used during co-loading of 500 mL of colloid (VOLUHES, HES 130/0.4, 6% I.V., Polifarma, Türkiye) for spinal anesthesia and spinal anesthesia induced hypotension was treated with 10 mg of ephedrine (only available vasopressor drug in the country) in IV bolus doses in both groups.
- Despite all parturients in both groups received 10 mg of IV metoclopramide prophylactically, parturients in the ERAS implemented group received IV 1.5 mg of the 5-HT3 antagonist granisetron additionally. In both groups, in case of risk factors for intraoperative and postoperative nausea and vomiting (PONV), IV 4 mg of dexamethasone was added.
- To maintain normothermia body temperature loss was prevented using under-patient-mattress-blankets and warmers along with the control of the operating theatre temperature.
- After the delivery of the baby, uterotonics were administered as per hospital guidelines (50 microgram of carbetocin IV bolus was given and followed by 20 IU of oxytocin in 1000 ml of normal saline infusion was started at a rate of 2.5-7.5 IU/ hour) in both groups.
Delayed cord clamping was not performed in any of the groups by the obstetricians.
Step 3. Postoperative Components
- In both groups who are at risk for deep vein thrombosis, prophylaxis was provided using pneumatic compression stockings.
- Blood glucose monitoring was conducted only in diabetic patients and those with symptoms of hypoglycemia during follow-up.
- In the ERAS implemented group, the diet management plan was as follows:
- drinking clear water was started at 2 h postoperatively
- eating liquid diet (regime I or II) was started at 4 h
- Regime I (R-I) is a clear liquid diet that contains pulp-free, grain-free liquid drinks such as sweetened tea, fruit juice, compote water, lemonade, meat and chicken broth.
- Regime II (R-II) is a soft diet that consists of soft, easily chewable and digestible foods such as; light soups, mashed and boiled potatoes, puddings and liquid drinks, etc.
- eating normal diet (regime III-IV) was started at 6 h In the control group, the oral intake -diet management plan was as follows:
- drinking water at 6 h postoperatively
- eating diet R I-II a few h later
- eating diet R III-IV after 1st flatus
- Parturients in the ERAS implemented group were encouraged to chew gum with early feeding, while patients in the control group were not.
- The urinary catheter was removed just before mobilization in the ERAS implemented group, whereas it was removed when urine output reached to 1000 mL as per clinical conventional procedure in the control group.
- In the ERAS implemented group, mother-baby contact to promote early bonding was established, and both mother and baby were encouraged for breastfeeding. In the control group, only mother-baby contact was facilitated without proactive breastfeeding encouragement.
- Prior to discharge, both groups were asked to fill out the validated Turkish version of the ObsQoR-11 with 11-point Likert scale. These forms were collected.
Recorded parameters;
- maternal demographics, comorbidities with medications and history (drug allergy, surgical and obstetric)
- preoperative duration of fasting for fluid and solid food, time to intake of 1st postoperative water, regimen I-II and regimen III-IV
- time to mobilization, urinary catheter removal and flatus and LOS for mother (in hours)
- postoperative pain within 24 h of the surgery was assessed for all patients using VAS scores at postoperative 24 h in rest and extra analgesic requirement
- validated Turkish version of 11-item ObsQoR score with an 11-point numerical Likert scale (0 being strongly negative, 10 being strongly positive) resulting maximum score of 110.
- postoperative complications (hypoglycemia, hypotension, PONV)
- newborn demographics and Apgar scores, umbilical cord gas analysis, newborn LOS in days
- need for follow-up in the ward or newborn intensive care unit (NICU) for transient tachypnea of the newborn (TTN) or phototherapy
- status of mother-baby bonding and breastfeeding
Study design
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- In this interventional study, Enhanced Recovery After Surgery (ERAS) protocol for cesarean has been planned to apply to the parturients who accepted to participate to the study. Unfortunately randomization cannot be done since the strategy for assigning participants to apply ERAS intervention was based on the obstetric team's preference first. The rest of the parturients were regarded as the control group (standard care) who did not receive ERAS intervention.
| Arm | Type | Receives |
|---|---|---|
| STANDARD CARE (CONTROL) | No intervention | –Standard care as control includes ROUTINE preoperative, peroperative and postoperative approach of the institution for the management of cesraean delivery under spinal anesthesia. |
| ERAS PATHWAY | Experimental | Dietary Supplement: 25 gram of maltodextrin in 330 mL , Nutricia Fantomalt 4 Gram, Nutri Gıda Ürünleri San. ve Tic. A.Ş., Istanbul, Türkiye, 2 h prior to surgery., Behavioral: Mother baby bondingERAS INTERVENTION includes 3 steps: 1. preoperative components (face to face education/information about fasting, Cesarean Section and/or anesthesia, antimicrobial prophylaxis, breastfeeding preparation and support, fasting schedule, anemia screening-hemoglobin optimization if needed), 2. peroperative components (antibiotic and antiemetic prophylaxis, management of neuraxial anesthesia, maintenance of normothermia, uterotonic use), 3. postoperative components (early oral intake/urinary catheter removal/mobilization, early mother-newborn bonding and encouraged breastfeeding). |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- American Society of Anesthesiologists (ASA) II or III term pregnant women aged ≥18 years scheduled to undergo elective CS under spinal anesthesia between June 2021 and June 2023 in Gazi University
Key exclusion criteria (1 listed)
- Parturients younger than <18 years old with fetal compromise, ASA IV or V physical status and emergency cases, medical contraindication to regional anesthesia particularly spinal block
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 25 gram of maltodextrin in 330 mL , Nutricia Fantomalt 4 Gram, Nutri Gıda Ürünleri San. ve Tic. A.Ş., Istanbul, Türkiye, 2 h prior to surgery.Although 45 g of different carbohydrate solutions either Gatorade 54 g carbohydrate or clear apple juice 56 g carbohydrate in non-diabetic women have been recommended by SOAP, we preferred 25 g of carbohydrate, fantomalt, nutricia, diluted in the 330 mL in both diabetic and non-diabetic pregnant women. | Dietary supplement | ERAS PATHWAY |
| Mother baby bondingIn the ERAS implemented group, mother-baby contact to promote early bonding was established, and both mother and baby were encouraged for breastfeeding. In the control group, only mother-baby contact was facilitated without proactive breastfeeding encouragement. | Behavioural | ERAS PATHWAY |
Primary outcome
improved maternal recovery in term of ObsQoR in the ERAS pathway
Time frame: From enrollment to the end of ERAS or control postpartum 24 hours
Primary outcome measure is described as maternal recovery outcome measure determined by obstetric quality recovery score (ObsQoR) which has been known as a patient reported outcome mesaure (PROM) and neonatal outcome assessed by pediatricians. ObsQoR-11 scores with Likert scale corresponds to; zero being very poor and 110 being excellent
1 secondary outcome
implementation of maternal ERAS protocol improves newborn nutrition and breastfeeding
Time frame: From enrollment to the end of ERAS or control postpartum 24 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Dec 2024.
- Derived from this study: PubMed 40301800Ozdemir MG, Gunaydin B, Bayram M, Hirfanoglu IM. Effect of enhanced recovery after surgery (ERAS) protocol on maternal and fetal outcomes following elective cesarean section: an observational trial. BMC Pregnancy Childbirth. 2025 Apr 29;25(1):517. doi: 10.1186/s12884-025-07583-3.
- Individual participant dataSharing planned: Yes. only IPD used in the results publication
Related trials for Pregnant Women
Active, not recruitingObservational study
A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients
Atypical Hemolytic Uremic Syndrome(aHUS)
Recruiting
Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Meconium Exposure
Neonatal Respiratory Distress Related Conditions, Meconium
Recruiting
Feasibility of the "One-Finger Technique" for Identifying the Upper Left Ureter During Para-Aortic Lymphadenectomy
Ovary Cancer, Cervical Cancer
Not yet recruiting
Evaluating the Healthy Families PrEP Program for Women at Risk for HIV
HIV, Pregnancy
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 25 gram of maltodextrin in 330 mL , Nutricia Fantomalt 4 Gram, Nutri Gıda Ürünleri San. ve Tic. A.Ş., Istanbul, Türkiye, 2 h prior to surgery. and Mother baby bonding in people with Pregnant Women and Enhanced Recovery After Surgery (ERAS) Protocol, run by Gazi University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
improved maternal recovery in term of ObsQoR in the ERAS pathway (time frame: From enrollment to the end of ERAS or control postpartum 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06753058, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Dec 2024.